Health Care/Hospital

Alterity to present at the 7th International Congress of Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format fromFebruary 26-...

2021-02-26 20:45 6713

Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization

HANGZHOU, China, Feb. 26, 2021 /PRNewswire/ -- China National Medical Products Administration (NMPA) announced onFebruary 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the "Ad5-nCoV", trade name: Convidecia™). CanSino Biologics Inc. an...

2021-02-26 16:36 5522

Kyushu University Confirms HORIUCHI L-FUCOIDAN Inhibits Binding between ACE2 and Virus Spike Protein (Derived from COVID-19)

KURUME, Japan, Feb. 26, 2021 /PRNewswire/ -- FCC Horiuchi Co., Ltd. based in Kurume City,Fukuoka Prefecture, western Japan, has conducted an experiment in inhibiting binding between ACE2 and virus spike protein using HORIUCHI L-FUCOIDAN, manufactured by the company, in collaboration with a gradua...

2021-02-26 15:00 3574

ARANZ Medical's Silhouette® system becomes a national platform for wound telehealth assessments

CHRISTCHURCH, New Zealand, Feb. 25, 2021 /PRNewswire/ -- The US Department of Veteran's Affairs (VA) is establishingARANZ Medical's Silhouette solution as a VA national platform, enabling more VA Medical Centers to utilize Silhouette in their wound telehealth programs.

2021-02-26 09:39 2029

Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform

BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen's antibody discove...

2021-02-25 23:45 1917

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in the phase 3 piv...

2021-02-25 21:00 5141

Huami Corporation Announces Name Change to Zepp Health

BEIJING and CUPERTINO, Calif., Feb. 25, 2021 /PRNewswire/ -- Huami Corp . today announced it is changing its name internationally to Zepp Health Corp. (NYSE: ZEPP) and the ticker symbol of its American depositary shares listed on the NYSE to "ZEPP" to better reflec...

2021-02-25 20:56 9571

111 to Announce Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results on March 18, 2021

SHANGHAI, Feb. 25, 2021 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...

2021-02-25 19:00 4811

Zhuyeqing The Epitome of Chinese Green Tea Ranks High in the "2021 Global Top 10 Luxury Tea Brands"

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- On February 24, 2021, Chinese brand Zhuyeqingranked high in the "2021 Global Top 10 Luxury Tea Brands", a global list that is compiled exclusively by one of the top three brand valuation organizations, World Brand Lab, to rank the best international high-en...

2021-02-25 16:21 5315

Turnaround on track at Comvita

TAURANGA, New Zealand, Feb. 24, 2021 /PRNewswire/ -- Headlines * Reported NPAT $3.5M vs. ($13M) in PCP * Reported EBITDA* $10.6M vs. ($8.8M) in PCP, an improvement of $19.4M * Reported revenue $98.9M, +5.5% vs. PCP * Double-digit top and bottom-line growth in focus growth markets * Net ...

2021-02-25 07:38 7086

Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients

SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/ -- Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research ...

2021-02-25 07:00 2749

I-Mab Announces Upcoming Participation at March Conferences

SHANGHAI and GAITHERSBURG, Md., Feb. 24, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March....

2021-02-24 21:00 5031

Alternative meat startup Next Meats Co., Ltd and microalgae biotech company euglena Co., launch "NEXT Euglena Yakiniku EX" containing microalgae

TOKYO, Feb. 12, 2021 /PRNewswire/ -- Next Meats Co., LTD, the controlling shareholder of Next Meats Holdings, Inc. ("OTC: NXMH") announced that they had signed a joint product development agreement witheuglena Co., a biotech company also fromJapan which specializes in cultivating Euglena and Chlo...

2021-02-24 12:45 6109

WuXi Diagnostics Secures US$150 Million Series B Financing to Accelerate Market Penetration in Global Diagnostics Sector

SHANGHAI, Feb. 23, 2021 /PRNewswire/ -- WuXi Diagnostic Investment (Cayman) Limited ("WuXi Diagnostics") announced that it has completedUS$150 million in series B funding, joined by new investors including Thermo Fisher Scientific Inc. ("Thermo Fisher"), Shiyu Capital ("SHIYU"), ABC International...

2021-02-24 08:00 2787

Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.

TOKYO, Feb. 23, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS). HOS specializes in predictive analytics and clinical decision support that enable healthcare...

2021-02-24 07:00 9004

GBB Completes USD$3.8M Convertible Note Financing Led by Alibaba Hong Kong Entrepreneurs Fund

HONG KONG, Feb. 23, 2021 /PRNewswire/ -- Great Bay Bio Holdings Limited (hereinafter referred to as "GBB") today announced it has completed aUSD$3.8M Convertible Note Financing. Alibaba Hong Kong Entrepreneurs Fund (hereinafter referred to as "AEF") led the investment round with participation fro...

2021-02-23 23:00 2430

Gracell Biotechnologies to Report Fourth Quarter and Fiscal 2020 Financial Results on Tuesday, March 9, 2021

SUZHOU and SHANGHAI, China, Feb. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it plans to release ...

2021-02-23 21:00 8174

Surgical Wait Times Technology Now Available in Australia and New Zealand

Fastest Growing Canadian Health Technology Company Expands Into ANZ SYDNEY, Feb. 23, 2021 /PRNewswire/ -- Wait times in both Australia and New Zealand are too long and how patients are admitted for surgery hasn't changed in decades. Unlike elsewhere, the process is unnecessarily antiquated and ...

2021-02-23 05:00 1133

Curocell announces Korean FDA clearance of the IND for CRC01, a first in kind immune checkpoint receptors downregulated CD19 CAR-T therapy

DAEJEON, South Korea, Feb. 22, 2021 /PRNewswire/ -- Curocell, Inc., a clinical-stage biotech developing next-generation CAR-T (OVIS™) therapies, announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved its Phase 1/2 clinical study application forCRC01, CD19 CAR-T cell the...

2021-02-22 22:00 1655

ABclonal Biotechnology Completes $93 Million Series C Financing

WOBURN, Mass., Feb. 22, 2021 /PRNewswire/ -- ABclonal Biotechnology, a global life science tools and services provider, recently completed its$92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital. Other new and existing shareholders, such as Si...

2021-02-22 20:00 1895
1 ... 293294295296297298299 ... 306